Satoshi Serada

Research field (1)： Molecular biology

Research theme for competitive and other funds (10)：

2022 - 2025 抗癌剤の薬効を増強できる抗体を用いた抗体薬物複合体による卵巣癌治療薬
2022 - 2025 Development of a companion diagnostics toward for Glypican-1 targeted antibody-based medicine
2020 - 2023 頭頸部扁平上皮癌におけるSOCS1新規遺伝子治療確立のための基礎研究
2019 - 2022 Functinal analysis of Glypican-1 in cancer stem-like cells and developmnt of antibody-based therapy
2016 - 2019 Development antibody-drug conjugate targeting glypican-1 for novel therapy of esophageal squamous cell carcinoma.

Show all

Papers (161)：

Masashi Funauchi, Satoshi Serada, Kosuke Hiramatsu, Eiji Funajima, Mizuki Kanda, Yoshikazu Nagase, Satoshi Nakagawa, Tomoharu Ohkawara, Minoru Fujimoto, Yuji Suzuki, et al. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. International journal of cancer. 2024. 154. 3. 425-433
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. International journal of cancer. 2023. 152. 12. 2580-2593
Mizuki Kanda, Satoshi Serada, Kosuke Hiramatsu, Masashi Funauchi, Kengo Obata, Satoshi Nakagawa, Tomoharu Ohkawara, Okinori Murata, Minoru Fujimoto, Fumiko Chiwaki, et al. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. 2023. 35. 100853-100853
Yoshikazu Nagase, Kosuke Hiramatsu, Masashi Funauchi, Mayu Shiomi, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Ai Miyoshi, Shinya Matsuzaki, Eiji Kobayashi, et al. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer. BMC Cancer. 2022. 22. 1
永瀬慶和, 平松宏祐, 中川慧, 松崎慎哉, 木村敏啓, 世良田聡, 上田豊, 仲哲治, 木村正. 抗LSR抗体は子宮体癌においてアポトーシスを誘導し抗腫効果を発揮する(Anti-LSR monoclonal antibody induces apoptosis and exerts a significant antitumor effect in endometrial cancer). 日本癌学会総会記事. 2022. 81回. E-3009

ｍore...

MISC (152)：

Yuka Shibata, Hideki Nakajima, Kimiko Nakajima, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shigetoshi Sano. Leucine-rich alpha-2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY. 2021. 4. 4. 87-89
山本竜駒, 樺山一哉, 樺山一哉, 兼田加珠子, 兼田加珠子, 世良田聡, 仲哲治, 篠原厚, 篠原厚, 深瀬浩一, et al. Evaluation of antibody kinetics and anti-tumor effect using alpha emitter labeled antibody. 日本化学会春季年会講演予稿集(Web). 2021. 101st
梶本恵津子, 藤本穣, 松崎慎哉, 遠藤誠之, 世良田聡, 木村正, 仲哲治. 新規炎症マーカーであるLRG(leucine richα2 glycoprotein)の子宮内胎児感染における有用性. 日本臨床免疫学会総会プログラム・抄録集. 2018. 46回. 132-132
飯島英樹, 松岡克善, 新崎信一郎, 世良田聡, 水野慎大, 藤本穰, 金井隆典, 仲哲治. 【Immunology〜領域を超えた挑戦〜】IBD領域炎症性腸疾患の新たなバイオマーカー leucine-rich α2 glycoprotein(LRG)について. クリニシアン. 2018. 65. 10. 940-945
高田友美, 吉野潔, 平松宏祐, 中川慧, 世良田聡, 中嶋綾, 遠藤洋子, 松崎慎哉, 上田豊, 井上正宏, et al. プロテオミクスを用いた子宮頸部小細胞がんと肺小細胞がんの比較(Proteomics reveals similar protein expression profiles of uterine cervical and lung small cell carcinoma). 日本癌学会総会記事. 2018. 77回. 746-746

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page